Vitor Magnus Martins

Vitor Magnus Martins

Auto-generated profile, based on publicly available information

Vitor Magnus Martins

Universidade Federal do Rio Grande do Sul

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
MMMarcelo Miglioranza
Marcelo Miglioranza
LGLuna Gargani
Luna Gargani
RSRoberto Tofani Sant'ANna
Roberto Tofani Sant'ANna
MRMarciane Maria Rover
Marciane Maria Rover
VMVitor Magnus Martins
Vitor Magnus Martins
TLTiago Luiz Luz Leiria
Tiago Luiz Luz Leiria

1 January 2008 in Clinical and Experimental Hypertension
Verified
Journal Article
Closed access
PGPatrícia Guerrero
Patrícia Guerrero
FFFlávio Danni Fuchs
Flávio Danni Fuchs
LMLeila M. Moreira
Leila M. Moreira
VMVítor M. Martins
Vítor M. Martins
CBCarolina Bertoluci
Carolina Bertoluci
MGMiguel Gus
Miguel Gus
A large proportion of patients with hypertension need a second drug to reach satisfactory control of blood pressure (BP), but there are few well-designed controlled trials comparing the efficacy of drugs added as a second option. In a double-blind randomized clinical trial, 82 patients with uncontrolled BP, receiving hydrochlorothiazide 25 mg daily, were selected to receive amiloride 2.5–5 mg/day (n = 39) or enalapril 10–20 mg/day (n = 43). Ambulatory blood pressure monitoring (ABPM) was done before and after 12-weeks of treatment. Office BP was measured in the 4th, 8th, and 12th weeks. The doses of amiloride and enalapril were doubled in the fourth week, and propranolol was added in the 8th week if office BP was above 140/90 mm Hg. There was a greater BP reduction in patients treated with enalapril. The ABPM δ values between the groups were 3.6 ± 2.2, 3.9 ± 2.2, and 1.1 ± 2.7 mmHg for 24-h, daily, and nightly systolic blood pressure, respectively, favoring enalapril. For diastolic blood pressure (DBP), the deltas were 1.7 ± 2.0, 3.2 ± 1.5, and 1.2 ± 1.9 mmHg, respectively (p = 0.039 for daily DBP). Office SBP decreased more and sooner in patients allocated to enalapril (p = 0.003). More patients taking amiloride required propranolol to control BP (p = 0.035). Potassium increased 0.3 mEq/L on the average in both groups. Cough, albeit predominantly mild, was reported more frequently by participants treated with enalapril. We conclude that enalapril is more effective than amiloride to lower BP of patients on hydrochlorothiazide with uncontrolled BP.

27 December 2021 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Closed access
PDF file
FFFilipe Ferrari
Filipe Ferrari
RSRafael S. Scheffel
Rafael S. Scheffel
VMVítor M. Martins
Vítor M. Martins
RSRaul D Santos
Raul D Santos
RSRicardo Stein
Ricardo Stein

1 January 2021 in Clinics
Verified
Journal Article
Open access
FFFilipe Ferrari
Filipe Ferrari
VMVítor M. Martins
Vítor M. Martins
MTMarcelo Teixeira
Marcelo Teixeira
RSRaul D Santos
Raul D Santos
RSRicardo Stein
Ricardo Stein
The novel coronavirus disease (COVID-19) showed increased morbidity and mortality rates and worse prognosis in individuals with underlying chronic diseases, especially cardiovascular disease and its risk factors, such as hypertension, diabetes, and obesity. ...

1 January 2021 in Clinics
Verified
Journal Article
Open access
FFFilipe Ferrari
Filipe Ferrari
VMVítor Magnus Martins
Vítor Magnus Martins
FFFlávio Danni Fuchs
Flávio Danni Fuchs
RSRicardo Stein
Ricardo Stein
Among the multiple uncertainties surrounding the novel coronavirus disease (COVID-19) pandemic, a research letter published in The Lancet implicated drugs that antagonize the renin-angiotensin-aldosterone system (RAAS) in an unfavorable prognosis of COVID-19. ...

8 February 2022 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
VMVítor M. Martins
Vítor M. Martins
PZPatrícia K. Ziegelmann
Patrícia K. Ziegelmann
LHLucas Helal
Lucas Helal
FFFilipe Ferrari
Filipe Ferrari
MLMarcelo B. Lucca
Marcelo B. Lucca
FFFlávio Danni Fuchs
Flávio Danni Fuchs
Background: The use of thiazide (T) diuretics for the treatment of hypertension may be associated with adverse metabolic effects, which can be minimized by combining thiazides with potassium-sparing (PS) diuretics. The additional blood pressure (BP)-lowering effect provided by the addition of a PS diuretic is unclear. Due to a large number of drugs in the T diuretics class, and the possible difference between them, there is a need to identify the best available evidence for health decision-making. This systematic review with network meta-analysis aims to compare the antihypertensive efficacy of T diuretics alone or in combination with a PS diuretic in patients with primary hypertension, as well as the safety of such drugs through the measurement of drug-related adverse events. Methods: A comprehensive electronic search will be conducted in six electronic bibliographic databases (PubMed/MEDLINE, Cochrane Library, Embase, Web of Science, Scopus, Lilacs), a registration database (ClinicalTrials.gov), and Educational Resources Information Center (ERIC [ProQuest]), published from inception to the date of the search. The search will be updated towards the end of the review. A hand search of the reference sections of the included studies and cited studies will also be performed. In case of missing data, authors will be contacted by e-mail or academic social networking sites whenever possible. To be included in the review, studies must be double-blind randomized controlled trials evaluating T diuretics alone or in combination with PS diuretics in patients with primary hypertension. The primary outcome measure will be office BP. Ambulatory BP monitoring (ABPM), non-melanoma skin cancer, major adverse cardiovascular events, laboratory parameters, and the number of withdrawals will be included as secondary outcomes. The results will be quantitatively summarized using differences between the mean change from baseline or differences between means for quantitative outcomes and relative risk for dichotomous outcomes. Results will be presented as mean or relative risk with credible intervals through a league table. The treatments will also be ranked using the surface under the cumulative ranking curve method. The risk of bias will be assessed through the RoB 1.0 tool. Discussion: To the best of our knowledge, this review will be the first to synthesize currently available evidence on the antihypertensive efficacy of different T diuretics alone or in combination with PS diuretics in adults with hypertension. The goals of hypertension treatment are to control high BP and to reduce associated cardiovascular morbidity and mortality, using the most appropriate therapy. Thiazides are widely used for pharmacological treatment due to their demonstrated effectiveness in reducing BP, favorable safety profile, and low cost. The results of this study will provide evidence regarding the best therapeutic strategies with T and PS diuretics, evidencing interventions with better antihypertensive efficacy and safety profile. Trial registration: This systematic review and network meta-analysis was prospectively registered at the PROSPERO database (CRD42018118492).